Severe Rhodococcus equi pneumonia following hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib in hepatocellular carcinoma: a case report
Abstract
Rhodococcus equi is a Gram-positive aerobic bacterium primarily associated with pulmonary infections in animals. Although rare in humans, such infections typically affect immunocompromised individuals, often presenting with severe pulmonary manifestations such as lung abscesses or cavitary pneumonia. This report describes a patient with advanced hepatocellular carcinoma (HCC) who developed cavitary pneumonia after receiving hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib. Diagnosis of Rhodococcus equi infection was confirmed via bronchoalveolar lavage fluid (BALF) analysis. The infection was successfully managed with an adjusted antibiotic regimen of imipenem/cilastatin, levofloxacin, and amikacin.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.